Probiotics for maintenance of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 3, 2020, Pages

  Iheozor Ejiofor, Zipporah ^a   Kaur, Lakhbir ^a   Gordon, Morris ^a,d   Baines, Patricia Anne ^b   Sinopoulou, Vasiliki ^a   Akobeng, Anthony K ^c  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b Sidra Medicine ^*  (United Kingdom)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^d BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PROBIOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE EVENT; AVASCULAR NECROSIS; BACTERIAL STRAIN; CLINICAL EFFECTIVENESS; FEMUR HEAD NECROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG EMBOLISM; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; ADULT; AGED; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; MESALAMINE; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; YOUNG ADULT;

EID: 85081042121     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007443.pub3     Document Type: Review

References (81)

1. Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology 2019; 27:465-73. x-wiley/crsRef/12916529
2. Copaci I, Chiriac G. Maintenance of remission of ulcerative colitis: prebiotics and dietary fiber. United European Gastroenterology Journal 2014; 1:A375. x-wiley/crsRef/12916531
3. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1997; 11(5):853-8. x-wiley/crsRef/2677479
4. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11):1617-23. x-wiley/crsRef/2677481
5. Matsuoka K, Uemura Y, Kanai T. Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Digestive Diseases and Sciences 2018; ns:1-10. x-wiley/crsRef/12916533 [org/10.1007/s10620-018-4946-2]
6. NCT02361957. The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients (CUPIDO). clinicaltrials.gov/ct2/show/NCT02361957 first posted 12 February 2015. x-wiley/crsRef/12916535
7. Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O'Donoghue, D, Kiely B, et al. A one year, randomised, double-blind, placebo controlled trial of a Lactobacillus or a Bidifobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006; 130(4 Suppl 2):A44. x-wiley/crsRef/2677503
8. Vejdani R, Bahari A, Zadeh AM, Azmi M, Ebrahimi-Daryani N, Hashtroudi AA, et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences January-March 2017;69(1):24-8. x-wiley/crsRef/12916537
9. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis 2011; 5(2):115-21. x-wiley/crsRef/2677487
10. Yasushi Y, Akihiro Y, Ryuichi F, Koji S, Aisaku O, Kentaro N, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World Journal of Gastroenterology 2015; 21(19):5985-94. x-wiley/crsRef/12916539
11. Zocco MA, dal Verme LZ, Armuzzi A, Nista EC, Papa A, Candelli M. Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology 2003; 124(4):A201. x-wiley/crsRef/12916541
12. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006; 23(11):1567-74. x-wiley/crsRef/2677489
13. Ahmed J, Reddy BS, Molbak L, Leser TD, Macfie J. Impact of probiotic on colonic microflora in patients with colitis: A prospective double blind randomised crossover study. International Journal of Surgery 2013; 11(10):1131-6. x-wiley/crsRef/12916543
14. Ballini A, Santacroce L, Cantore S, Bottalico L, Dipalma G, Tope S, et al. Probiotics efficacy on oxidative stress values in inflammatory bowel disease: a randomized double-blinded placebo-controlled pilot study. Endocrine, Metabolic & Immune Disorders - Drug Targets 2019; 19(3):1-8. x-wiley/crsRef/12916545
15. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. Journal of Gastroenterology and Hepatology 2002; 17(8):818-24. x-wiley/crsRef/12916547
16. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al. Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology 2004; 10(10):1521-5. x-wiley/crsRef/2677491
17. Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Annals of Pharmacotherapy 2010; 44(3):565-71. x-wiley/crsRef/12916549
18. Faubion WA, Sandborn WJ. Probiotic therapy with E. Coli for ulcerative colitis: take the good with the bad. Gastroenterology 2000; 118(3):630-1. x-wiley/crsRef/12916551
19. Folwaczny C. Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment. Zeitschfrift de Gastroenterologie 2000; 38(6):547-50. x-wiley/crsRef/12916553
20. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, et al. Randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009; 25(5):520-5. x-wiley/crsRef/2677495
21. Henker J, Müller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Zeitschrift fur Gastroenterologie 2008; 46(9):874-5. x-wiley/crsRef/2677497
22. IRCT20120415009475N5. Evaluation of the effects of Saccharomyces Boulardii on pain and quality of life in children with Inflammatory Bowel Disease (IBD) [Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD)]. www.irct.ir/trial/32179 (registration date 10 October 2018). x-wiley/crsRef/12916555 [IRCT: https://www.irct.ir/trial/32179]
23. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition 2002; 22(1):56-63. x-wiley/crsRef/2677499
24. Ishikawa H, Matsumoto S, Ohashi Y, Imoaka A, Setoyama H, Umesaki Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study. Digestion 2011; 84(2):128-33. x-wiley/crsRef/12916557
25. Li K, Zhang CF, Xia YH, Li Z J, Han Y. Efficacy of probiotics on ulcerative colitis and its mechanism. Zhonghua Weichang Waike Zazhi 2013; 16(4):336-9. x-wiley/crsRef/12916559
26. Liu P, Sun L, Zhang ZH, Zhang P, Zhang J. Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology 2014; 22(22):3344-8. x-wiley/crsRef/12916561
27. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology 2009; 104(2):437-43. x-wiley/crsRef/2677501
28. NCT00268164. Lactobacilus acidophilus and Bifidobaceterium animalis subsp. Lactis maintenance treatment in ulcerative colitis. clinicaltrials.gov/show/NCT00268164 First received 22 December 2005. x-wiley/crsRef/12916563
29. NCT00374725. Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus. clinicaltrials.gov/show/NCT00374725 First posted 11 September 2006. x-wiley/crsRef/12916565
30. NCT00803829. Sunbiotic treatment of ulcerative colitis patients. clinialtrials.gov/show/NCT00803829 First posted 8 December 2008. x-wiley/crsRef/12916567
31. NCT00951548. Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis. clinicaltrials.gov/show/NCT00951548 First posted 4 August 2009. x-wiley/crsRef/12916569
32. NCT01772615. Treatment of ulcerative colitis with ciprofloxacin and E. Coli Nissle. clinicaltrials/gov/show/NCT01772615 First posted 21 january 2013. x-wiley/crsRef/12916571
33. Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2016; 160(3):372-7. x-wiley/crsRef/12916573
34. Pelech T, Fric P, Fixa B, Komarkova O. Comparison of mutaflor and mesalazine in the maintenance treatment of inactive ulcerative colitis. Prakticky Lekar 1998; 78(10):556-8. x-wiley/crsRef/12916575
35. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354(9179):635-9. x-wiley/crsRef/2677483
36. Rohatgi S, Ahuja V, Makharia GK, Rai T, Das P, Dattagupta S, et al. VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial. BMJ Open Gastroenteroilogy 2015; 2(1):e000018. x-wiley/crsRef/12916577
37. Sanchez-Morales A, Perez-Ayala MF, Cruz-Martinez M, Arenas-Osuna J, Ramirez-Mendoza P, Ceniceros RA, et al. Efectividad de probioticos sobre sintomas, histologia, y tolerancia alimentaria en colitis ulcerativa. Revista Medica del Instituto Mexicano del Seguro Social 2019; 57(1):9-14. x-wiley/crsRef/12916579
38. Shadnoush M, Hosseini RS, Mehrabi Y, Delpisheh A, Alipoor E, Faghfoori Z, et al. Probiotic yogurt affects pro- and anti-inflammatory factors in patients with inflammatory bowel disease. Iranian Journal of Pharamceutical Research 2013; 12(4):929-36. x-wiley/crsRef/12916581
39. Solovyeva O. Probiotics can extend remission of ulcerative colitis. Journal of Crohn's and Colitis 2014; 8:221. x-wiley/crsRef/12916583
40. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology 2010; 105(10):2218-27. x-wiley/crsRef/12916585
41. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 1999; 13(8):1103-8. x-wiley/crsRef/2677507
42. Zhang J. Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology 2018; 26(6):373-7. x-wiley/crsRef/12916587
43. Fan H, Du J, Liu X, Zheng WW, Zhuang ZH, Wang CD, et al. Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. Turkish Journal of Gastroenterology 2019; 30(8):680-5. x-wiley/crsRef/12916589
44. Fang W, Cai Q. Effect of mesalazine combined with bifid on inflammatory response and rectal-anal dynamics in patients with ulcerative colitis. World Chinese Journal of Digestology 2018; 26(10):594-600. x-wiley/crsRef/12916591
45. Huang M, Chen Z, Lang C, Chen J, Yang B, Xue L, et al. Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors. Pakistan Journal of Pharmaceutical Sciences 2018; 31(6):2891-5. x-wiley/crsRef/12916593
46. Shi XH, Tan FP, Jiang WH. Bacillus subtilis and Enterococcus faecium enteric-coated capsules combined with mesalazine for treatment of patients with ulcerative colitis: Efficacy and impact on serum levels of SOD, MDA, interleukins, and TNF-α. World Chinese Journal of Digestology 2018; 26(12):748-54. x-wiley/crsRef/12916595
47. Yilmaz I, Dolar ME, Özpinar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish Journal of Gastroenterology 2019; 30(3):242-53. x-wiley/crsRef/12916597
48. Zhang Y, Wu M, Chen Y. Effects of adjuvant therapy with bifidobacterium quadruplex on lipid peroxidation injury indices, inflammatory factors and immune function in patients with ulcerative colitis. World Chinese Journal of Digestology 2018; 26(22):1348-54. x-wiley/crsRef/12916599
49. NCT03415711. PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis (PROREM UC). clinicaltrials.gov/ct2/show/NCT03415711 First posted 30 January 2018. x-wiley/crsRef/12916601
50. NCT03565939. Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO) (PROCTO). clinicaltrials.gov/ct2/show/NCT03565939 First posted 21 June 2018. x-wiley/crsRef/12916603
51. NCT03798210. Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis (COLUS). clinicaltrials.gov/ct2/show/NCT03798210 First posted 9 January 2019. x-wiley/crsRef/12916605
52. Liang J. Multistrain Probiotics Reduces UC Depression and Anxiety Scores. clinicaltrials.gov/ct2/show/NCT04006977 First posted 5 July 2019. x-wiley/crsRef/12916607
53. Baron JH, Connell AM, Lenard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. British medical journal 1964; 1:89-92.
54. Cleynen I. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016; 387(10014):156-67.
55. Cohen RD. Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmaology and Therapeutics 2010; 31(7):693-707.
56. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003; 52(3):370-6.
57. Fabia R, Ar'Rajab A, Johansson ML, Willen R, Andersson R, Molin G, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-induced colitis in the rat. Scandinavian Journal of Gastroenterology 1993; 28(2):155-62.
58. Fiorino G. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therapeutic Advances in Gastroenerology 2016; 9(4):503-12.
59. McMaster University GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.).Available from gradepro.org.
60. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557-60.
61. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
62. Jairath V, Zou GY, Parker CP, MacDonald JK, AlAmeel T, Al Beshir M et al. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database of Systematic Reviews 2017, Issue 9. [DOI: 10.1002/14651858.CD011572.pub2]
63. Kennedy RJ, Hoper M, Deodhar K, Kirk SJ, Gardiner KR. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scandinavian Journal of Gastroenterology 2000; 35(12):1266-71.
64. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126(6):1504-17.
65. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116(5):1107-14.
66. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121(3):580-91.
67. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, Issue 10. [DOI: 10.1002/14651858.CD005573.pub2]
68. National Institute for Health and Care Excellence. Ulcerative Colitis Mangagement NG130. https://www.nice.org.uk/guidance/ng130 2019.
69. Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK. Probiotics to prevent infantile colic. Cochrane Database of Systematic Reviews 2019, Issue 3. [DOI: 10.1002/14651858.CD012473.pub2]
70. Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enterocolitis: new opportunities for translational research. Pathophysiology 2014; 21(1):35-46.
71. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999; 281:1110-1.
72. The Cochrane Collaboration The Nordic Centre. Copenhagen: The Cochrane Collaboration, 13th June 2014.Available at https://community.cochrane.org/help/tools-and-software/revman-5.
73. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases 2002; 8(2):71-80.
74. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
75. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases 2002; 8(6):399-406.
76. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. British medical journal 1956; 1:1315-1318.
77. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, Part 1: ambulatory care—an evidence-based guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition 2018; 67(2):257-91. [DOI: 10.1097/mpg.0000000000002035]
78. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2016; 389(10080):1756-70.
79. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD000544.pub4]
80. Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007443]
81. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD007443.pub2]